These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33144213)

  • 1. New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction.
    Heerspink HJL; Kohan DE; de Zeeuw D
    Kidney Int; 2021 Feb; 99(2):346-349. PubMed ID: 33144213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic transformation for diabetic kidney disease.
    Tuttle KR; Cherney DZI
    Kidney Int; 2021 Feb; 99(2):301-303. PubMed ID: 33509348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
    Heerspink HJL; Xie D; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Perkovic V; Rossing P; Parving HH; de Zeeuw D;
    J Am Soc Nephrol; 2021 Nov; 32(11):2900-2911. PubMed ID: 34551995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.
    Kohan DE; Lambers Heerspink HJ; Coll B; Andress D; Brennan JJ; Kitzman DW; Correa-Rotter R; Makino H; Perkovic V; Hou FF; Remuzzi G; Tobe SW; Toto R; Parving HH; de Zeeuw D
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1568-74. PubMed ID: 26153128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose co-transporter-2 inhibitors increase Klotho in patients with diabetic kidney disease: A clinical and experimental study.
    Mora-Fernández C; Sánchez-Niño MD; Donate-Correa J; Martín-Núñez E; Pérez-Delgado N; Valiño-Rivas L; Fernández-Fernández B; Ortiz A; Navarro-González JF
    Biomed Pharmacother; 2022 Oct; 154():113677. PubMed ID: 36942605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
    Zhou Y; Chi J; Huang Y; Dong B; Lv W; Wang YG
    Diabet Med; 2021 Jan; 38(1):e14411. PubMed ID: 33000477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A
    Waijer SW; Gansevoort RT; Bakris GL; Correa-Rotter R; Hou FF; Kohan DE; Kitzman DW; Makino H; McMurray JJV; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
    Clin J Am Soc Nephrol; 2021 Dec; 16(12):1824-1832. PubMed ID: 34853062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of exposure response relationship of atrasentan between North American and Asian populations.
    Heerspink HJ; Makino H; Andress D; Brennan JJ; Correa-Rotter R; Coll B; Davis JW; Idler K; Kohan DE; Liu M; Perkovic V; Remuzzi G; Tobe SW; Toto R; Parving HH; de Zeeuw D
    Diabetes Obes Metab; 2017 Apr; 19(4):545-552. PubMed ID: 27981738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
    de Zeeuw D; Coll B; Andress D; Brennan JJ; Tang H; Houser M; Correa-Rotter R; Kohan D; Lambers Heerspink HJ; Makino H; Perkovic V; Pritchett Y; Remuzzi G; Tobe SW; Toto R; Viberti G; Parving HH
    J Am Soc Nephrol; 2014 May; 25(5):1083-93. PubMed ID: 24722445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria.
    Shah N; Perkovic V; Kotwal S
    Expert Rev Clin Pharmacol; 2022 Jul; 15(7):827-842. PubMed ID: 35912871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
    Smeijer JD; Koomen J; Kohan DE; McMurray JJV; Bakris GL; Correa-Rotter R; Hou FF; Januzzi JL; Kitzman DW; Kolansky DM; Makino H; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
    JACC Heart Fail; 2022 Jul; 10(7):498-507. PubMed ID: 35772861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.
    Koomen JV; Stevens J; Mostafa NM; Parving HH; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2018 Aug; 20(8):2019-2022. PubMed ID: 29603851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.
    Veenit V; Heerspink HJL; Ahlström C; Greasley PJ; Skritic S; van Zuydam N; Kohan DE; Hansen PBL; Menzies RI
    Nephrol Dial Transplant; 2023 Sep; 38(10):2289-2297. PubMed ID: 37102226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Webb DJ; Coll B; Heerspink HJL; Andress D; Pritchett Y; Brennan JJ; Houser M; Correa-Rotter R; Kohan D; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Busch R; Pergola P; Parving HH; de Zeeuw D
    Drugs R D; 2017 Sep; 17(3):441-448. PubMed ID: 28831752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).
    Andress DL; Coll B; Pritchett Y; Brennan J; Molitch M; Kohan DE
    Life Sci; 2012 Oct; 91(13-14):739-42. PubMed ID: 22326504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
    Koomen JV; Stevens J; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Parving HH; Perkovic V; Tobe SW; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2021 Feb; 23(2):561-568. PubMed ID: 33184931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
    Smeijer JD; Kohan DE; Rossing P; Correa-Rotter R; Liew A; Tang SCW; de Zeeuw D; Gansevoort RT; Ju W; Lambers Heerspink HJ
    Cardiovasc Diabetol; 2023 Sep; 22(1):251. PubMed ID: 37716952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New pharmacological strategies for protecting kidney function in type 2 diabetes.
    Muskiet MHA; Wheeler DC; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 May; 7(5):397-412. PubMed ID: 30579729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
    Koomen JV; Stevens J; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan DE; Makino H; McMurray JJV; Parving HH; Perkovic V; Tobe SW; de Zeeuw D; Heerspink HJL
    Clin Pharmacol Ther; 2021 Jun; 109(6):1631-1638. PubMed ID: 33338269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.